Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Last trade$5.74
Day change-$0.075 (-1.29%)
Day range$5.55 – $6.37
Volume326,699
Market cap$299M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$298.72M
Price / earnings
—
Price / book
0.95×
Price / sales
0.46×
EV / sales
0.97×
EV / EBITDA
5.65×
Profitability
Earnings per share
-$5.07
Return on assets
-26.2%
Return on equity
-83.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.62×
Current ratio
4.58×
Quick ratio
2.27×
Cash ratio
1.44×
Cash flow
Price / cash flow
1.49×
Price / free cash flow
1.59×
Free cash flow
$188.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EBS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$110M
$234.3M
$156.1M
$148.7M
$231.1M
$140.9M
$222.2M
$194.7M
Cost of revenue
$80.8M
$97.1M
$72M
$84.9M
$85.9M
$66.9M
$88.5M
$118M
Gross profit
$29.2M
$137.2M
$84.1M
$63.8M
$145.2M
$74M
$133.7M
$76.7M
Selling, general and administrative
$46.5M
$44.6M
$46.6M
$51.1M
$38.9M
$43.7M
$52.4M
$60.8M
Research and development
$9.4M
$9.2M
$10.5M
$12.1M
$13.5M
$12.5M
$15.1M
$9.1M
Total operating expenses
$66.5M
$262.3M
$73.6M
$91.7M
$68.7M
$72.4M
$83.8M
$86.2M
Operating income
-$37.3M
-$125.1M
$10.5M
-$27.9M
$76.5M
$1.6M
$49.9M
-$9.5M
Interest expense
-$9.7M
-$10M
-$11M
-$14.7M
-$15.2M
-$14.7M
-$14.7M
-$14.8M
Income before taxes
-$36.4M
-$166.3M
$13.4M
-$50.7M
$57.6M
-$16.8M
$92.7M
-$27.6M
Income taxes
-$3.7M
$13.9M
$6.6M
$3.9M
$6.4M
-$4.8M
$24.7M
$3.7M
Net income
-$32.7M
-$180.2M
$6.8M
-$54.6M
$51.2M
-$12M
$68M
-$31.3M
Net income attributable to common shareholders
-$32.7M
-$180.2M
$6.8M
-$54.6M
$51.2M
-$12M
$68M
-$31.3M
EBITDA
-$20.3M
$90.2M
$34M
$7.8M
$99.9M
$25.1M
$75.3M
$16.5M
Basic earnings per share
-$0.64
-$3.49
$0.13
-$1.05
$0.96
-$0.22
$1.25
-$0.58
Diluted earnings per share
-$0.64
-$3.49
$0.07
-$0.93
$0.91
-$0.22
$1.19
-$0.61
Recent news
Company coverage with links to the original publishers.
Emergent BioSolutions updated its full-year 2026 revenue guidance to $600-645 million amid competitive pressures in its commercial drug business. The company is implementing $40 million in annualized cost-cutting measures and expanding international medical countermeasures sales to 13 countries. While NARCAN faces pricing pressure and market competition, it maintains its leading market position. Management is focusing on operational efficiency, debt reduction, and pipeline execution to support long-term recovery.
Swedish Orphan Biovitrum beat Q3 earnings expectations with $0.71 EPS versus consensus of $0.62, and revenue of $945.87 million surpassed estimates by 4.09%. However, the stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release, suggesting near-term underperformance despite strong year-to-date gains of 29.7%.
Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain.
Pomerantz LLP announced investigations into potential securities fraud at Emergent BioSolutions, Klarna Group, and Dr. Reddy's Laboratories. Emergent reported a $191.3 million impairment charge on its NARCAN asset group and cut full-year revenue guidance by 10.8%, citing increased competitive intensity. The stock fell 29.58% on the news.
The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.